However, large observational studies including patients with type 2 diabetes and obesity have suggested improved survival outcomes in patients with preexisting NETs using GLP-1 or GIP/GLP-1 RAs [15]. This evidence concerns the gene GIP and obesity due to melanocortin 4 receptor deficiency.